TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00783692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vedolizumab
Description: Vedolizumab for intravenous infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous infusion
Study: NCT01657318

Intervention type: OTHER
Intervention: Olivamine containing wound care products
Description: Continuous wound care with Olivamine containing products until wound closure. Intake of dietary supplement of 1 capsule for 60 days.
Study: NCT03519386

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: G2-TR intraocular implant containing travoprost
Description: Provided in Arm/Group descriptions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham surgery + active-comparator eye drops
Description: Sham surgery plus postoperative active-comparator eye drops (timolol maleate ophthalmic solution, 0.5%).
Study: NCT01316354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread types
Description: Bread with 50 g available carbohydrate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread types
Description: Bread with 50 g available carbohydrate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread types
Description: Bread with 50 g available carbohydrate
Study: NCT02929069

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ESTEEM
Description: ESTEEM is a 10-session intervention based on the Unified Protocol, an individually-delivered CBT intervention with efficacy for reducing stress-sensitive mental health disorders (e.g., depression, anxiety) by enhancing emotion regulation skills; reducing avoidance patterns; and improving motivation and self-efficacy for behavior change.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CMHT
Description: CMHT is the current standard of care for LGB individuals who seek mental, behavioral, or sexual health care is LGB-affirmative therapy.The practice of LGB-affirmative therapy is outlined across 21 guidelines published by the American Psychological Association.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VCT
Description: Voluntary Counselling and Testing (VCT).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VCT
Description: Voluntary Counselling and Testing (VCT).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VCT
Description: Voluntary Counselling and Testing (VCT).
Study: NCT00362752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Description: 400 mg po bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 400 mg po bid
Study: NCT01289743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept 25 mg subcutaneously twice a week
Study: NCT00765089

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Isolation of pulmonary veins with Bipolar radiofrequency ablation
Study: NCT01498874

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gevokizumab
Description: Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gevokizumab
Description: Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
Study: NCT01368120

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IV Clear™ Dressing
Description: Polyurethane film, silicone adhesive dressing with chlorhexidine and silver
Study: NCT01316354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread types
Description: Bread with 50 g available carbohydrate
Study: NCT03767101

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: In all three treatment arms, licensed therapists/trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. All treatments are based on individualized treatment plans for each patient. Therapists are supervized by an CBT expert therapist in the outpatient treatment center. On average every forth session is supervized. The total duration of treatment is variable, oriented on patients symptoms and treatment goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: In all three treatment arms, licensed therapists/trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. All treatments are based on individualized treatment plans for each patient. Therapists are supervized by an CBT expert therapist in the outpatient treatment center. On average every forth session is supervized. The total duration of treatment is variable, oriented on patients symptoms and treatment goals.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive behavioral therapy
Description: In all three treatment arms, licensed therapists/trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. All treatments are based on individualized treatment plans for each patient. Therapists are supervized by an CBT expert therapist in the outpatient treatment center. On average every forth session is supervized. The total duration of treatment is variable, oriented on patients symptoms and treatment goals.
Study: NCT03647332

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cooled RFA treatment
Description: cooled radiofrequency ablation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid Drug
Description: steroid injection
Study: NCT03408340

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paravertebral Nerve Block
Description: Participants will be induced for anesthesia with propofol 3 milligram/kilogram (mg/kg) or ketamine 2mg/kg (if there is intravenous (IV) access) or sevoflurane with 1 microgram/kilogram (mcg/kg) of fentanyl and 1.2 mg/kg rocuronium once IV access is established. A NIRS pad will be used for cerebral oximetry as well as another NIRS pad for spinal cord oximetry. The patient will be intubated, and then will be positioned laterally for the nerve block at approximately the left T3-4 level. A linear ultrasound probe with a sterile sheath will be used to provide imaging for the paravertebral nerve block. The injected solution will be 1 milliliter/kilogram (mL/kg) of 0.2% ropivacaine with 5 mcg/mL (1:200,000) epinephrine. Fentanyl may be used as needed for additional analgesia and anesthesia will be maintained with sevoflurane. The skin will not be infiltrated with additional local anesthetic at the conclusion of the case.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Anesthesia
Description: Participants in this arm will be induced for anesthesia with propofol 3mg/kg or ketamine 2mg/kg (if there is intravenous access) or sevoflurane with 1 mcg/kg of fentanyl and 1.2 mg/kg rocuronium once IV access is established. The patient will be intubated; intravenous and intra-arterial access will be obtained and the patient will be positioned for surgery. Fentanyl may be used as needed for additional analgesia and anesthesia will be maintained with sevoflurane. The skin will be infiltrated at the conclusion of surgery with less than 1 mL/kg of 0.25% bupivacaine with epinephrine 1:200,000.
Study: NCT04054882

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabin-IPV and DTaP
Description: simultaneously administration of Sabin-IPV and DTaP

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sabin-IPV
Description: administration of Sabin-IPV only

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP
Description: administration of DTaP only
Study: NCT02702999

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clinically-indicated ultrasound
Description: Routine third trimester care with clinically-indicated ultrasound (control)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Serial third trimester ultrasound
Description: Ultrasound evaluation for fetal growth and amniotic fluid will be performed every 4 weeks starting at 30 weeks (intervention group). Thus, if they continue to term, there will be 3 additional ultrasounds exams (30, 34 and 38 weeks).
Study: NCT01475786

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control- Placebo (normal saline)
Description: subjects will receive thirty-two (32) 0.5 mL injections of normal saline on Day 0 and Day 14.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control- Placebo (normal saline)
Description: subjects will receive thirty-two (32) 0.5 mL injections of normal saline on Day 0 and Day 14.
Study: NCT04894409

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mouthwash and nose rinse with the AgNPs solution
Description: The experimental group was instructed to do mouthwash and nose rinse with the AgNPs solution for the prevention of SARS-CoV-2 infection in health workers

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mouthwashes and nose rinse in a conventional way
Description: The control group was instructed to do mouthwashes and nose rinse in a conventional way
Study: NCT02359539

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regenerative therapy
Description: Periosteal pedicle, Platelets rich fibrin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regenerative therapy
Description: Periosteal pedicle, Platelets rich fibrin
Study: NCT04893941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM310
Description: IL-4Rα monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM310
Description: IL-4Rα monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM310
Description: IL-4Rα monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM310
Description: IL-4Rα monoclonal antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03236363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVI-da10! active breaks
Description: MOVI-da10! active breaks, is a physical activity intervention that consists on two daily physical activity breaks of 10 minutes of duration (intensity: 4-6 METs, Heart rate ≥150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVI-da10! integrated physical activity
Description: MOVI-da10! integrated lessons, is a physical activity intervention that consists on two daily cognitive demanding physical activity breaks of 10 minutes of duration (intensity: 2-3 METs, Heart rate \<150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
Study: NCT01652963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reed and Clements Training Task
Description: see study arm: Reed and Clements Training Task. Training task developed to improve cognitive mediation skills in people with intellectual disabilities.
Study: NCT05531617

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation
Description: Study groups Intubated with Macintosh or cmac video laryngoscopes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation
Description: Study groups Intubated with Macintosh or cmac video laryngoscopes
Study: NCT01886534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Heart Failure Discharge Summary to Primary Care Physicians©
Description: At hospital discharge, in addition to usual care, the Study Nurse will fax an introduction letter and a 1-page comprehensive Standardized Heart Failure Discharge Summary to Primary Care Physicians© integrating Canadian Cardiovascular Society HF guideline recommendations to the patient's family physician.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Heart Failure Discharge Summary to Primary Care Physicians©
Description: At hospital discharge, in addition to usual care, the Study Nurse will fax an introduction letter and a 1-page comprehensive Standardized Heart Failure Discharge Summary to Primary Care Physicians© integrating Canadian Cardiovascular Society HF guideline recommendations to the patient's family physician.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized education sessions
Description: Following baseline data collection, and prior to hospital discharge or within 72 hours of discharge, all patient/caregiver dyads in the intervention group will receive a 45-60-minute standardized education session with the study nurse according to individualized patient learning needs, aimed to ensure similar baseline level of heart failure self-care knowledge. Verbal (teach-back) and written information from the Trial of Education And Compliance in Heart dysfunction (TEACH) RCT will be provided to all patient/caregiver dyads. Information regarding self-care such as dietary restrictions, exercise guidelines, weight and symptom monitoring (shortness of breath, swelling of the ankles) included in the education package will be reviewed. The teaching sessions will occur at 1 week, 2 weeks, 1 month and 2 months post-discharge.
Study: NCT01368120

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tegaderm CHG™
Description: Polyurethane film, polyacrylate adhesive and a polyol hydrogel containing 2% w/w chlorhexidine gluconate

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Silicone Vehicle Control Dressing
Description: Polyurethane film with silicone adhesive dressing, without antimicrobials
Study: NCT01886534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized education sessions
Description: Following baseline data collection, and prior to hospital discharge or within 72 hours of discharge, all patient/caregiver dyads in the intervention group will receive a 45-60-minute standardized education session with the study nurse according to individualized patient learning needs, aimed to ensure similar baseline level of heart failure self-care knowledge. Verbal (teach-back) and written information from the Trial of Education And Compliance in Heart dysfunction (TEACH) RCT will be provided to all patient/caregiver dyads. Information regarding self-care such as dietary restrictions, exercise guidelines, weight and symptom monitoring (shortness of breath, swelling of the ankles) included in the education package will be reviewed. The teaching sessions will occur at 1 week, 2 weeks, 1 month and 2 months post-discharge.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart Failure Diuretic Decision Support Tool for Patient Self Management©
Description: Each patient/caregiver dyad will be provided a paper-based Heart Failure Diuretic Decision Support Tool for Patient Self Management© at hospital discharge assisting in the titration of their oral furosemide. The purpose of this tool will be to assist the patient/caregiver in keeping track of signs and symptoms of worsening heart failure. The family physician will also be provided an access to similar decision support tool for management of clinical deterioration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart Failure Diuretic Decision Support Tool for Patient Self Management©
Description: Each patient/caregiver dyad will be provided a paper-based Heart Failure Diuretic Decision Support Tool for Patient Self Management© at hospital discharge assisting in the titration of their oral furosemide. The purpose of this tool will be to assist the patient/caregiver in keeping track of signs and symptoms of worsening heart failure. The family physician will also be provided an access to similar decision support tool for management of clinical deterioration.
Study: NCT00002784

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Filgrastim 10 mg/kg/d sc for 6 days after randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CMF regimen
Description: Cyclophosphamide 100 mg/m2 orally days 1 - 14, methotrexate 40 mg/m2 iv days 1 and 8, 5-fluorouracil 600 mg/m2 iv days 1 and 8. Repeat every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: For high-dose EC arm: cyclophosphamide 4 gm/m2 iv as 4 divided doses. For standard chemotherapy arm: cyclophosphamide 600 mg/m2 iv day 1 of 21-day EC cycles, and cyclophosphamide 100 mg/m2 orally on days 1-14 of 28-day CMF cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: For high-dose EC arm: cyclophosphamide 4 gm/m2 iv as 4 divided doses. For standard chemotherapy arm: cyclophosphamide 600 mg/m2 iv day 1 of 21-day EC cycles, and cyclophosphamide 100 mg/m2 orally on days 1-14 of 28-day CMF cycles.
Study: NCT01886534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital talking scale
Description: Prior to hospital discharge, the patient/caregiver dyad will be provided a digital, talking scale to measure their weight in their home setting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital talking scale
Description: Prior to hospital discharge, the patient/caregiver dyad will be provided a digital, talking scale to measure their weight in their home setting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Patients allocated to the usual care group will receive the hospital-approved heart failure management booklet which meets evidence-based requirements for outpatient heart failure management. Patients will meet with the hospital HF nurse-clinician (standard at this institution) to review heart failure symptoms and signs, diet and exercise recommendations. They will also meet with the ward pharmacist prior to hospital discharge to review medications and side effects. Referral to the HF clinic and any HF initiative will be left to the discretion of the most responsible physician.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Patients allocated to the usual care group will receive the hospital-approved heart failure management booklet which meets evidence-based requirements for outpatient heart failure management. Patients will meet with the hospital HF nurse-clinician (standard at this institution) to review heart failure symptoms and signs, diet and exercise recommendations. They will also meet with the ward pharmacist prior to hospital discharge to review medications and side effects. Referral to the HF clinic and any HF initiative will be left to the discretion of the most responsible physician.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Patients allocated to the usual care group will receive the hospital-approved heart failure management booklet which meets evidence-based requirements for outpatient heart failure management. Patients will meet with the hospital HF nurse-clinician (standard at this institution) to review heart failure symptoms and signs, diet and exercise recommendations. They will also meet with the ward pharmacist prior to hospital discharge to review medications and side effects. Referral to the HF clinic and any HF initiative will be left to the discretion of the most responsible physician.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Patients allocated to the usual care group will receive the hospital-approved heart failure management booklet which meets evidence-based requirements for outpatient heart failure management. Patients will meet with the hospital HF nurse-clinician (standard at this institution) to review heart failure symptoms and signs, diet and exercise recommendations. They will also meet with the ward pharmacist prior to hospital discharge to review medications and side effects. Referral to the HF clinic and any HF initiative will be left to the discretion of the most responsible physician.
Study: NCT01107028

Intervention type: OTHER
Intervention: Standard pulmonary rehabilitation program
Description: At the assigned time, subjects will complete a six-week, outpatient pulmonary rehabilitation program at any local center that has such a program.

Intervention type: OTHER
Intervention: Standard pulmonary rehabilitation program
Description: At the assigned time, subjects will complete a six-week, outpatient pulmonary rehabilitation program at any local center that has such a program.
Study: NCT04221594

Intervention type: PROCEDURE
Intervention: Invasive Cardiac Catheterization (ICA)
Description: Invasive functional measurements will be performed to assess the functional significance of specific lesions by means of FFR and CFR, and to test the presence of microvascular disease by means of IMR in all vessels for which the procedures are feasible. In summary, a 5- to 7-F guide catheter without side holes is used to engage the coronary artery and a pressure-temperature sensor-tipped guidewire introduced. The pressure sensor is positioned at the distal segment of a target vessel, and intracoronary nitroglycerine (100-200 mg) administered before each measurement. The best systolic and diastolic phase (located between 30-50%, and 60-75% of the cardiac cycle) will be selected for successive processing as it allows a relative motion free visualization of the main vessels and the myocardium.